Macroglobulinemia de Waldenström

A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies

Fase II

NCT05006716

Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)

Sem fase

NCT00923507

Study to Assess Change in Disease Activity of Oral Venetoclax in Adult Participants With Recurring Relapsed or Refractory (R/R) Waldenström Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)

Sem fase

NCT07387471

Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma

Sem fase

NCT04840602

NCT05294731 · Treatment of Chinese Participants With B-Cell Malignancies W…Recrutando

🟢 Recrutando agora

15 pesquisas recrutando participantes. Converse com seu médico sobre a possibilidade de participar.

PHASE1, PHASE2

NCT05006716 · A Dose-Escalation and Expansion Study of BGB-16673 in Partic…Recrutando

PHASE1, PHASE2

NCT00923507 · Natural History Study of Monoclonal B Cell Lymphocytosis (MB…Recrutando

NCT07387471 · Study to Assess Change in Disease Activity of Oral Venetocla…Recrutando

NCT04840602 · Testing the Combination of Venetoclax and Rituximab, in Comp…Recrutando

NCT06561347 · Zanubrutinib, Bendamustine, Rituximab Prev. Untreated WMRecrutando

NCT05640102 · Observational Study Evaluating the Efficacy and Safety of Za…Recrutando

NCT07249905 · Dose Escalation and Dose Expansion Study of MDX2003 in Patie…Recrutando

PHASE1, PHASE2

NCT05093153 · Spanish Registry of Patients With IgM Monoclonal Gammopathie…Recrutando

NCT05544019 · Study of SGR-1505 in Mature B-Cell NeoplasmsRecrutando

PHASE1

NCT07169331 · A Study to Evaluate the Efficacy and Safety of Zanubrutinib …Recrutando

PHASE4

NCT06986174 · A Phase 2 Study to Evaluate the Safety and Efficacy of Pacri…Recrutando

NCT07231952 · A Study of Pirtobrutinib, Venetoclax, and Rituximab in Peopl…Recrutando

NCT06712810 · Q702 for the Treatment of Patients With Hematologic Malignan…Recrutando

PHASE1

NCT07173790 · Watch and Wait or Worry and Wait in Indolent LymphomaPor convite

Outros ensaios clínicos

272 ensaios clínicos encontrados, 24 ativos.

Distribuição por fase

NCT02180724 · An Open-label, Phase 2 Study of ACP-196 in Subjects With Wal…Ativo

NCT02952508 · Study of Iopofosine I-131 (CLR 131) in Select B-Cell Maligna…Ativo

NCT02339922 · Ixazomib Citrate and Rituximab in Treating Patients With Ind…Ativo

NCT05952037 · A Study to Investigate Efficacy and Safety of BCL2 Inhibitor…Ativo

NCT01815749 · Genetically Modified T-cell Infusion Following Peripheral Bl…Ativo

PHASE1

Ver todos no ClinicalTrials.gov

🧪 Está conduzindo uma pesquisa?

Divulgue para pacientes e familiares que acompanham esta doença.

Divulgar pesquisa →

Publicações mais relevantes

🥉Melhor nível de evidência: Relato de caso

Timeline de publicações

1.053 papers (10 anos)

Mostrando amostra de 200 publicações de um total de 1.053

#1

Prognosis and treatment of plasmablastic lymphoma in the United States: a multicenter retrospective study.

Blood cancer journal2026 Mar 23

Plasmablastic lymphoma (PBL) is a rare, aggressive AIDS-related lymphoma observed in patients with immunosuppressed states as well as in immunocompetent individuals. We sought to determine survival outcomes, prognostic factors, and optimal treatment regimens in a large, contemporary cohort of patients with PBL in the United States. We performed a multicenter, retrospective cohort study, including 344 patients diagnosed with PBL between 2005 and 2022. Patients were stratified into cohorts according to underlying immune status. Survival outcomes were calculated using Kaplan-Meier statistics, with cohort-specific survival outcomes adjusted using propensity score-based weighting. Factors associated with outcomes were assessed via multivariable models using multiple imputation. The median age at diagnosis was 53 years, most patients were male (n = 270), and many had HIV (n = 164). The median OS was 5.0 years, with a median PFS of 1.4 years. Patients living with HIV had the best outcomes, whereas patients with prior organ transplantation had the worst outcomes. Use of higher intensity chemotherapy regimens and use of a proteasome inhibitor in the frontline setting did not show survival benefit. While there was no clear optimal treatment approach in the frontline setting, the median OS of 5.0 years is dramatically improved compared with historical controls.

#2

Quantitative MYD88 L265P and flow cytometry levels for outcome determination in IgM gammopathies: the SAL-TO study.

Blood advances2026 Mar 19

Waldenström macroglobulinemia (WM) is a rare indolent B-cell lymphoproliferative disorder, often preceded by a history of IgM monoclonal gammopathy of undetermined significance (IgM-MGUS). In this retrospective multicentric study, we collected real-life data from 577 IgM gammopathy patients (221 symptomatic WM, sWM, 245 asymptomatic WM, aWM, 111 IgM-MGUS) from 22 Spanish Centers, with a validation cohort of 166 patients (73 sWM, 71 aWM, 22 IgM-MGUS) from University Hospital of Torino, Italy. Median overall survival (OS) was 126.7 months for the Spanish cohort and 202.8 for the Torino cohort. Multivariate analysis identified significant age > 65 years, male gender, diagnosis of sWM and beta-2-microglobulin >3 as significant predictors for shorter OS. Additionally, age > 65 years, bone marrow (BM) biopsy infiltration, haemoglobin <11.5 g/dL and platelets <100.000/mmc were associated with shorter time to first treatment (TTFT). Pooling data from both cohorts revealed that baseline BM quantitative MYD88 L265P/MYD88 WT ratio > 0.162 (either by ddPCR or quantitative PCR) together with multiparameter flow cytometry (MFC) infiltration >4.39% had a significant impact on OS and TTFT; the combination of MYD88 and MFC levels allowed to stratify patients into high-, intermediate-, and low-risk groups, with high-risk IgM gammopathy patients showing increased disease-related death in competing risk analysis.

#3

Clinical Characteristics and Treatment Outcomes of Patients with Waldenstrom Macroglobulinemia.

Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion2026 Mar

Waldenstrom macroglobulinemia (WM) is a rare B-cell lympho-proliferative disorder. There is limited data from India regarding the characteristics and outcomes of patients with WM. We describe here the patients with WM treated at our center over the course of the past 15 years. This was a single center, retrospective analysis. Patients fulfilling the diagnosis of WM who were treated at our center between 2009 and 2023 were included in the study. Fifty-five patients were included in the study for analysis. The median age was 62 years with a Male: Female ratio of 3.2:1. Most patients (n = 42; 76.4%) had symptoms attributable to WM, while 5 patients (9.1%) had Immunoglobulin M (IgM) related symptoms and 8 patients (14.5%) had both. The median hemoglobin of the cohort was 7.4 g/dl and the median serum IgM level was 4.87 g/L. MYD88 mutation testing was done in 30 patients and was positive in 16 (53.3%). The most common first line therapy was chemo-immunotherapy (n = 36; 65.5%). Most common chemo-immunotherapy was Bendamustine-Rituximab followed by Rituximab-Cyclophosphamide-Dexamethasone. The overall response rate and major response rate to front-line therapy was 78.2% and 69.1% respectively. The median follow-up for the entire cohort was 30 months. Fourteen patients died during follow-up with the most common cause being progressive disease (n = 6; 42.9%). The median Event-free Survival, Time to Next therapy and Overall Survival were 45 months, 51 months and 150 months respectively. In our WM case series from India, we found a low incidence of MYD88 mutations with comparable treatment outcomes to western literature.

#4

Evolution of tumor subclones and T-cell dynamics underlie variable ibrutinib responses in Waldenström macroglobulinemia.

Blood2026 Feb 11

To elucidate the molecular basis underlying differential response and resistance to ibrutinib in Waldenström's macroglobulinemia (WM), we conducted a prospective phase II trial (ClinicalTrials.gov; NCT02604511) of ibrutinib monotherapy in treatment-naïve patients. Seventy-four sequential bone marrow (BM) aspirates from 17 patients, collected from baseline through 48 treatment cycles, were profiled using single-cell multi-omics. BM cells segregated primarily into B/plasma cell and T-cell compartments. Longitudinal clonal tracking of malignant B/plasma cells identified three distinct evolutionary patterns: "evolution" (early clone contraction with late clone expansion and increasing genomic complexity), "devolution" (early clone expansion with late clone contraction and genomic simplification), and "no-evolution" (stable clonal architecture). The "evolution" pattern was strongly associated with disease progression, whereas "devolution" correlated with durable clinical response. Transcriptomic profiling of resistant clones enabled development and validation of the Waldenström's Ibrutinib Prediction (WIP) score, which predicted treatment response at baseline. Within the WIP signature, LYN emerged as a key regulator; LYN knockdown or inhibition significantly increased WM cell sensitivity to ibrutinib, suggesting a rational combinatorial strategy. In parallel, GZMB⁺ CD8⁺ effector-memory (TEM) cells expanded post-treatment in progressing patients and co-existed with tumor "evolution". These cells exhibited persistently impaired cytotoxic programs (e.g., GNLY), a de-differentiated memory-like state, elevated PDCD1 expression, and reduced TCR diversity. Together, this study provides the first single-cell framework of tumor clonal evolution and T-cell dysfunction under ibrutinib in WM; introduces the WIP score as a predictive biomarker for treatment response; and identifies actionable tumor-intrinsic and immune mechanisms driving resistance.

#5

POD24 is a Novel Determinant of Prognosis in Patients with Waldenström Macroglobulinemia.

Blood advances2026 Jan 07

Waldenström macroglobulinemia (WM) is characterized by recurrent MYD88 and CXCR4 mutations, whose prognostic value in chemoimmunotherapy-treated patients remains unclear. Moreover, the typically prolonged progression-free survival (PFS) correlates inconsistently with overall survival (OS), underscoring the importance of examining other surrogates. Progression of disease within 24 months (POD24), an established early endpoint, delineates functionally high-risk patients in other indolent lymphomas. This international study evaluated 253 patients receiving frontline fixed-duration bendamustine-rituximab (BR), a common chemoimmunotherapy for WM. At median follow-up of 5.9 years, 5-year PFS and OS were 65% and 87%, respectively; 5-year PFS was similar between MYD88L265P (90%) and MYD88wild-type (WT) subcohorts (64% each, p=0.4). Among 89 patients with known CXCR4 status, the subcohort with CXCR4mutation (28%) had shorter PFS (median, 3.3 versus 8.8 years; HR 2.8, p=0.0036) and OS (HR 2.6, p=0.036) compared to CXCR4WT. POD24 occurred in 11.5% of patients who demonstrated inferior subsequent OS (5-year OS: 71% versus 86%; HR 3.1, p=0.005) and higher mortality (SMR 3.7), unlike the non-POD24 group, whose mortality was comparable to the matched general population (SMR 1.1). In conclusion, BR is effective, irrespective of the MYD88 status, but CXCR4 mutations and POD24 portend worse outcomes. Non-POD24 patients represent a cohort with distinctly favorable outcome.

Publicações recentes

Acalabrutinib in Waldenström macroglobulinemia yields durable responses with 5 years of follow-up.

Blood Adv2026 Apr 15

Optimizing treatment for Waldenström macroglobulinemia-associated acquired von Willebrand syndrome: a case report and literature review.

Front Oncol2026

Ring of fire cells: plasma cell-predominant relapse of Waldenström macroglobulinemia.

Blood2026 Apr 9

CD3xCD20 bispecific antibodies in transformed Waldenström macroglobulinemia/lymphoplasmacytic lymphoma.

Hemasphere2026 Mar

Bruton protein-tyrosine kinase (BTK) FDA-approved small molecule inhibitors used for the management of neoplastic and inflammatory disorders.

Pharmacol Res2026 Apr 3

Ver todas no PubMed

📚 EuropePMC1.017 artigos no totalmostrando 199

Prognosis and treatment of plasmablastic lymphoma in the United States: a multicenter retrospective study.

International journal of surgical pathology

Masquerading as an Interstitial Lung Disease: Intravascular Large B-Cell Lymphoma With Prominent Neo-Angiogenesis.

Quantitative MYD88 L265P and flow cytometry levels for outcome determination in IgM gammopathies: the SAL-TO study.

A real-world 10-year follow-up analysis of survival and safety of CD20-targeted therapy in patients with Waldenstrom macroglobulinemia.

Frontiers in oncology

Zanubrutinib in AL Amyloidosis Associated With Waldenström Macroglobulinemia and Other B-Cell Non-Hodgkin Lymphoma.

Final Report of a Phase II Study of Ibrutinib and Venetoclax in Previously Untreated Waldenström Macroglobulinemia.

An Atypical Presentation of Ecthyma Gangrenosum in a Patient With Waldenström Macroglobulinemia.

Journal of the peripheral nervous system : JPNS

CIDP With and Without Monoclonal Gammopathy of Undetermined Significance (MGUS): Comparison of Clinical Phenotype, Diagnostic Features, and Treatment Response.

What is your diagnosis? A spontaneous echo contrast in Waldenström macroglobulinemia.

Intensive care medicine

A single-center retrospective study suggests a potential benefit of BTK inhibitor-based therapy in patients with histologic transformation of Waldenström macroglobulinemia.

Annals of medicine

A Meta-analysis Investigating Response Rates with Continuous Bruton Tyrosine Kinase Inhibitor Monotherapies in the Treatment of B Cell Lymphomas.

Oncology and therapy

Venetoclax or Pirtobrutinib in Relapsed/Refractory Waldenström Macroglobulinemia: Clinical and Molecular Predictors and Sequencing Implications.

Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy

Advances and resistance adaptation in BTK-targeted therapy for B-cell malignancies.

Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion

Clinical Characteristics and Treatment Outcomes of Patients with Waldenstrom Macroglobulinemia.

Interference and failure: The challenge of high-concentration IgM monoclonal protein in capillary zone electrophoresis.

Clinical biochemistry

Type 2 diabetes and risk of non-Hodgkin lymphoma and multiple myeloma: a pooled analysis.

JNCI cancer spectrum

Evolution of tumor subclones and T-cell dynamics underlie variable ibrutinib responses in Waldenström macroglobulinemia.

Persistent Anemia Revealing Underlying B-cell Malignancies: A Report of Two Cases Highlighting a Diagnostic Gap in Primary Care.

Off-trial outcomes of zanubrutinib in Waldenström macroglobulinemia: the prognostic impact of CXCR4 and TP53 alterations.

Leukemia

Incidence, Prevalence, Survival and Mortality of Chronic Lymphocytic Leukaemia/Small Lymphocytic Lymphoma and Waldenström Macroglobulinaemia in Australia.

Cancer medicine

BTK Inhibition in Hematology: From CLL/SLL to Emerging Applications Across B-Cell and Immune Disorders.

Biomolecules

Clinical outcomes in newly diagnosed patients with Waldenström's macroglobulinaemia treated in a tertiary academic centre.

Clinicopathological features and management of IgM multiple myeloma and Waldenstrom macroglobulinemia.

Onychorrhexis and onychoschizia associated with ibrutinib therapy.

JAAD case reports

Quantitative MYD88L265P and CXCR4S338X analysis to assess clinical trial performance in Waldenstrom macroglobulinemia.

International journal of dermatology

Cutaneous Infiltration as an Indicator of Systemic Disease Progression in Waldenström Macroglobulinemia.

Characteristics and Outcomes of Finnish Patients with Waldenström Macroglobulinemia-A Real-World Study.

Retinal cases & brief reports

Immunogammopathy Maculopathy and Macular Schisis with En Face OCT.

Bruton tyrosine kinase inhibitors and invasive aspergillosis and mucormycosis: a case report and multi-center exploratory retrospective study.

ASM case reports

POD24 is a Novel Determinant of Prognosis in Patients with Waldenström Macroglobulinemia.

IgG-type lymphoplasmacytic lymphoma with light chain deposition disease.

CEN case reports

Case reports in oncological medicine

A Rare Case of Pyoderma Gangrenosum Pointing to Waldenström Macroglobulinemia.

Therapeutic advances in hematology

Ibrutinib oral suspension bioavailability and compatibility for optimal enteral administration route.

Journal of cellular and molecular medicine

The Direction of Modern Therapies in Waldenström Macroglobulinaemia.

Annals of African medicine

Immunoglobulin M Multiple Myeloma: Case Report of a Rare Variant of Multiple Myeloma with Diagnostic and Treatment Challenges.

Ophthalmic plastic and reconstructive surgery

Orbital Waldenström Macroglobulinemia With Angiopathic Paraprotein Deposition: A Case Report.

Molecular modeling of Waldenström macroglobulinemia.

The Australasian journal of dermatology

Cutaneous Infiltration of Waldenstrom's Macroglobulinaemia-A Two-Case Series of a Diagnostically Challenging Presentation.

Expert review of hematology

Avoiding serious treatment-emergent adverse events in Waldenström macroglobulinemia patients.

Late toxicity and long-term efficacy of first-line bendamustine and rituximab combination in patients with Waldenström macroglobulinemia.

Leukemia

European journal of cancer (Oxford, England : 1990)

Waldenström's macroglobulinemia: The LYSA pragmatic guidelines.

Case reports in hematology

Solitary Hepatic Plasmacytoma With IgM Monoclonal Gammopathy: A Case Report.

European journal of haematology

Time to Next Treatment Within 24 Months (TTNT24) as a Predictor of Survival in Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinemia: A Population-Based Observational Study.

Multi-omics analysis reveals a unique epigenetic signature in MYD88 wild-type Waldenstrom macroglobulinemia.

Haematologica

Zanubrutinib Combined With Rituximab in the Treatment of Bing-Neel Syndrome: A Case Report.

Clinical case reports

Long-term outcomes and treatment patterns in Waldenström macroglobulinemia patients who discontinue Bruton tyrosine kinase inhibitor (BTKi) therapy.

Extent of bone marrow infiltration predicts disease progression in asymptomatic Waldenström macroglobulinemia.

Discover oncology

A multicentre prospective phase II study of rituximab combined with bortezomib, lenalidomide and dexamethasone, followed by lenalidomide maintenance (R-VRD) in patients with Waldenström's macroglobulinaemia (KMM1803).

Biochemical analysis reveals aberrant and variable Immunoglobulin M composition in Waldenström macroglobulinemia and IgM monoclonal gammopathy of unknown significance.

Frontiers in immunology

Journal of medical case reports

Clonal identification and homology differentiate primary central nervous system lymphoma from non-central nervous system lymphoplasmacytic lymphoma: a case report.

Transformation and survival in patients with Waldenström macroglobulinemia: a population-based study.

Discover oncology

Soluble BCMA: a window into tumor burden monitoring in Waldenström macroglobulinemia?

Repurposing pacritinib to target MYD88-mutated Waldenström macroglobulinaemia.

Lymphoplasmacytic Lymphoma with IgA Paraprotein: a Case Report and Literature Review.

Clinical laboratory

Uncovering regulatory B-cell features associated with regulatory T-cell expansion and global T-cell exhaustion in Waldenström macroglobulinemia Myd88 L252P -like lymphoplasmacytic lymphomas.

HemaSphere

Diagnosis of patients with IgM monoclonal gammopathy due to analytical interference.

Clinical biochemistry

Successful Treatment of Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinemia Complicated by Severe Autoimmune Neutropenia With Rituximab and Bendamustine.

Bing-Neel Syndrome in Waldenström Macroglobulinemia: Updates on Clinical Management and BTK Inhibitor Efficacy.

Cancers

Diagnostics (Basel, Switzerland)

A Rare Combination: Cold Agglutinin Disease Followed by Waldenström Macroglobulinemia-A Case of Early Treatment Response.

Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi

[Transformation of lymphoplasmacytic lymphoma/Waldenström macroglobulinemia into diffuse large B-cell lymphoma: five cases report and literature review].

Clinical Utility of Monoclonal Gammopathy Testing in the Evaluation of Anemia.

Familial clusters and clinical features, complications, and outcomes in 1000 patients with Waldenström macroglobulinemia.

BCL-2 inhibition in Waldenström macroglobulinaemia and marginal zone lymphoma.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc

CD180 as a Robust Immunophenotypic Marker for Differentiating Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinemia From Marginal Zone Lymphoma.

Zanubrutinib‑Induced Symmetrical Soft Tissue Forearm Swelling in a Patient With Waldenström Macroglobulinemia.

Lymphoplasmacytic lymphoma with IgG-λ and free λ light chain paraprotein: A case report.

Medicine

Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi

[Waldenstrom macroglobulinemia with refractory pleural fluid complicated with chylothorax: a case report].

Detection of MYD88L265P Mutation by Allele-Specific Polymerase Chain Reaction in Atypical Lymphoplasmacytic Lymphoma.

Clinical case reports

Pathology oncology research : POR

Two B or not two B; the question of bendamustine dosing in low grade lymphoma.

A Case Report of Waldenstrom's Macroglobulinemia Interfering with Serum Total Bilirubin and Creatinine.

Clinical laboratory

Soluble BCMA as a biomarker reflecting tumor volume and treatment response in Waldenström macroglobulinemia.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Genomics Define Malignant Transformation in Myeloma Precursor Conditions.

SAGE open medical case reports

Zanubrutinib for high-risk Waldenström macroglobulinemia with complex karyotype and hyperleukocytosis: A case report and literature review.

Expanded CD16+CD56+Granzyme B+ NK like CD8+ T cells an off target effect of bruton's tyrosine kinase inhibitors in Waldenström macroglobulinemia.

Scientific reports

Causes of Death Among Waldenström Macroglobulinemia Patients: A Population-Based Study.

The American journal of case reports

A Rare Case of Waldenström Macroglobulinemia Presenting as Bilateral Bloody Pleural Effusion and Pancytopenia.

Defining IgM Multiple Myeloma.

Journal of clinical and experimental hematopathology : JCEH

Bruton tyrosine kinase inhibitor in non-IgM lymphoplasmacytic lymphoma: a case report and literature review.

Membranous nephropathy preceding Bing-Neel syndrome: successful treatment with tirabrutinib.

Journal of nephrology

Rhode Island medical journal (2013)

Utility of Plasma Exchange in a Patient with Waldenström Macroglobulinemia and Recurrent Angioedema Secondary to C1 Esterase Inhibitor.

Genomic landscape of IgM-MGUS and patients with stable or progressive asymptomatic Waldenström macroglobulinemia.

The American Journal of dermatopathology

Monoclonal Cryoglobulinemia Clinically Mimicking Leukocytoclastic Vasculitis: A Case Report and Literature Review.

The journal of applied laboratory medicine

The Transformative Role of Mass Spectrometry in Diagnosing and Monitoring Monoclonal Gammopathies and Plasma Cell Disorders.

Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti

Description of TEMPI syndrome in Waldenström's macroglobulinemia.

International journal of hematology

Massive pleural effusion as the initial presentation of Waldenström macroglobulinemia: rare extramedullary involvement.

Cancer chemotherapy and pharmacology

Effect of plasma exchange on tirabrutinib plasma concentration in a patient with lymphoplasmacytic lymphoma: A case report.

European journal of haematology

Serum B-Cell Maturation Antigen as a Biomarker for Predicting Outcomes and Monitoring Patients With Waldenström Macroglobulinemia.

The Journal of the Association of Physicians of India

An Unusual Presentation of IgM Myeloma.

Future oncology (London, England)

Zanubrutinib in the treatment of Waldenström Macroglobulinemia.

Outcomes after transition from ibrutinib to zanubrutinib in patients with Waldenström macroglobulinemia from the ASPEN study.

Case reports in hematology

Coexistence of Essential Thrombocythemia and Waldenström Macroglobulinemia: A Case Report.

Value in health regional issues

Epidemiology, Real-World Treatment, and Economic Burden of Waldenström Macroglobulinemia: A Comprehensive Analysis Based on Anonymized Claims Data Between 2010 and 2022.

Distinct molecular subtypes in Waldenström macroglobulinemia.

Journal of clinical and experimental hematopathology : JCEH

Rapidly progressive fatal hepatic failure due to IgM-related AL amyloidosis in Waldenström's macroglobulinemia: an autopsy case report.

Mesenteric Mass Causing Bowel Obstruction in Waldenström Macroglobulinemia.

An Extremely Rare Cause of Protein-Losing Enteropathy: Waldenström Macroglobulinemia.

ACG case reports journal

The Impact of Tirabrutinib Monotherapy for the Treatment of Bing-Neel Syndrome: A Multicenter Retrospective Study.

The American Journal of dermatopathology

Simultaneous Presentation of Cutaneous Waldenström Macroglobulinemia and Acalabrutinib-Related Toxicity.

Current risk stratification and staging of multiple myeloma and related clonal plasma cell disorders.

Leukemia

Uncommon Entities, Uncommon Challenges: A Review of Rare Plasma Cell Disorders.

Hematology reports

Current issues in molecular biology

Waldenström Macroglobulinemia: The Role of TP53 Mutations in Disease Progression and Therapeutic Response.

Cancer reports (Hoboken, N.J.)

Progression of IgM Monoclonal Gammopathy of Renal Significance (MGRS) to Symptomatic Waldenström Macroglobulinemia: A Case Report.

SOHO State of the Art Updates and Next Questions | The Optimal Management of Waldenström Macroglobulinemia.

Long-term follow-up of venetoclax monotherapy in previously treated patients with Waldenström macroglobulinemia.

Ibrutinib plus rituximab vs ibrutinib monotherapy in patients with Waldenström macroglobulinemia: a pooled analysis.

Monoclonal Gammopathy of Renal Significance in a Patient With Cryoglobulinemia and Nephrotic Syndrome: A Case Report.

Genomic and immune profiling of prognostic risk groups in IgM gammopathy reveals novel biomarkers beyond MYD88 L265P.

Frontiers in immunology

Low-Grade B-Cell Neurolymphomatosis: A Case Series and Diagnostic Insight.

World neurosurgery

Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi

[Zanubrutinib treatment of Waldenström macroglobulinemia complicated by cryoglobulinemia: a case report].

Second Primary Malignancies and Disease Transformation in Patients With Symptomatic Waldenström's Macroglobulinemia.

Emergency medicine clinics of North America

Hyperviscosity Syndrome: An Oncologic Emergency.

Pirtobrutinib is an Effective Salvage Treatment After Ibrutinib in Bing-Neel Syndrome.

Annals of laboratory medicine

MYD88 L265P Variant Detection with Droplet Digital PCR in Waldenström Macroglobulinemia: Clinical Implications as a Tumor Burden and Prognostic Marker.

American journal of ophthalmology case reports

Macular retinoschisis in a patient with multiple lymphoproliferative malignancies.

The Kaohsiung journal of medical sciences

Cystoid Macular Edema Secondary to Hyperviscosity Syndrome in Waldenström Macroglobulinemia: A Case Report of Multimodal Treatment Response and the Adjunctive Role of Acetazolamide.

Cutaneous macroglobulinosis with Waldenström macroglobulinemia and Bing-Neel syndrome: A case report.

JAAD case reports

European journal of haematology

The Amyloidosis Intersection: Dual Amyloid Types in a Single Host.

Diagnosis and Management of Waldenstrom's Macroglobulinemia.

Hematological oncology

Journal of clinical neuromuscular disease

Clinical and Electrodiagnostic Findings in Anti-myelin-Associated Glycoprotein Antibody Polyneuropathy: A Single Center Review.

Familial aspects of multiple myeloma and Waldenström macroglobulinemia: understanding the predisposition in relatives and the importance of early diagnosis.

Not just amyloidosis: the spectrum of Waldenstrom's macroglobulinemia-associated renal disease.

American journal of ophthalmology case reports

Uveal melanoma following Bruton's tyrosine inhibitor use for the treatment of hematologic malignancies.

Prospective study of immunogenicity to SARS-CoV-2 booster vaccines in multiple myeloma and Waldenström macroglobulinemia.

Final results of a multicentre pilot study evaluating brentuximab vedotin with cyclophosphamide, doxorubicin, etoposide and prednisone (BV-CHEP) for the treatment of aggressive adult T-cell leukaemia/lymphoma.

Amyloidosis-Related Cardiomyopathy Revealing Waldenstrom Macroglobulinemia: A Case Report.

Synchronous occurrence of Waldenström macroglobulinemia and HER2-positive gastric adenocarcinoma with gastrointestinal stromal tumor: a rare case report.

Frontiers in oncology

Report of Consensus Panel 3 from the 12th International Workshop on Waldenstrom's Macroglobulinemia on the management of patients with high-risk disease.

Report of Consensus Panel 2 from the 12th International Workshop on the management of Bing-Neel syndrome in patients with Waldenstrom's Macroglobulinemia.

Journal of cellular and molecular medicine

Phenotypic Profile of Waldenström Macroglobulinaemia B-Cells: Establishment of a Diagnosis Scoring System and Clinico-Biological Correlations.

Report of Consensus Panel 1 from the 12th International Workshop on the management of patients with IgM and Waldenstrom's Macroglobulinemia related neuropathy.

Evidence of the modified staging system and comparative performance of IPSS and revised IPSS in a Single-Center Asian cohort with Waldenström macroglobulinemia.

Report of Consensus Panel 6 from the 12th International Workshop on Waldenstrom's Macroglobulinemia on Diagnosis and Management of Transformed Waldenstrom's Macroglobulinemia.

Report of Consensus Panel 4 from the 12th International Workshop on Waldenstrom's Macroglobulinemia on the management of patients with non-IgM lymphoplasmacytic lymphoma.

Report of Consensus Panel 5 from the 12th International Workshop on Waldenstrom's Macroglobulinemia on the management of patients with intolerance or resistance to covalent BTK inhibitors.

Treatment of Anti-Myelin-Associated Glycoprotein (MAG) Antibody Neuropathy Using Zanubrutinib in a Patient With Waldenström Macroglobulinemia: A Clinical Vignette.

Waldenström Macroglobulinemia Diagnosed by Ultrasonography-Guided Biopsy of the Right Perinephric Tumor.

IJU case reports

A multiomic analysis of Waldenström macroglobulinemia defines distinct disease subtypes.

Targeting BCL2 in Waldenström macroglobulinemia: from biology to treatment management.

Frontiers in oncology

Journal of clinical apheresis

Early Recognition of Retinal Signs in Waldenström's Macroglobulinemia: Implications for Therapeutic Plasma Exchange.

Outcomes of the transformation to diffuse large B-cell lymphoma in hodgkin lymphoma and indolent B-cell non-Hodgkin lymphoma: a population-based study.

Annals of hematology

Clinical analysis of lymphoma with malignant solid tumor simultaneously: a retrospective case series.

Diagnostic pathology

Paraneoplastic leukocytoclastic vasculitis mimicking ulcus cruris as rare initial manifestation of smoldering myeloma IgG kappa.

Annals of hematology

Development and characterization of the novel MYD88 mutated, 6q deleted BCWM.2 cell line for Waldenström macroglobulinaemia.

Outcomes of patients with relapsed/refractory lymphoplasmacytic lymphoma/waldenström macroglobulinemia treated with venetoclax: a multicenter retrospective analysis.

Impact of Comorbidities on Patients With Waldenström Macroglobulinemia in Taiwan: A Multicenter Study.

JCO global oncology

Waldenström Macroglobulinemia and Chronic Myelomonocytic Leukemia: Case Report and Literature Review.

OncoTargets and therapy

Expert review of anticancer therapy

Current and emerging treatment perspectives for adults with Waldenström macroglobulinemia.

Journal of the National Comprehensive Cancer Network : JNCCN

CRE25-038: Worsening COPD From Hyperviscosity: A Case Report of Waldenström Macroglobulinemia.

Rare Cases of Escherichia coli-Induced Aortitis in Immunocompromised Patients.

JACC. Case reports

Bing-Neel Syndrome: A Missed Opportunity.

Waldenström Macroglobulinemia: 2025 Update on Diagnosis, Risk Stratification, and Management.

Mediterranean journal of hematology and infectious diseases

Waldenström Macroglobulinemia - A State-of-the-Art Review: Part 2- Focus on Therapy.

International journal of molecular sciences

CXCR4 Inhibition Enhances the Efficacy of CD19 Monoclonal Antibody-Mediated Extermination of B-Cell Lymphoma.

BMC cardiovascular disorders

From interference to insight: pseudo-lipidemia led to the diagnosis of Waldenström macroglobulinemia.

Depth of Response From Fixed-Duration Treatment Is Associated With Superior Survival in Waldenstrom Macroglobulinemia.

Composite mantle cell lymphoma with cryptic ins(11;2)(q13;p11.2p11.2)/IGK::CCND1 and lymphoplasmacytic lymphoma with MYD88 L265P mutation.

Cancer genetics

Clinical cancer research : an official journal of the American Association for Cancer Research

Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study.

American journal of clinical pathology

How I diagnose B-cell lymphoproliferative disorders with plasmacytic differentiation.

Clinical nuclear medicine

Seminal Vesicle Involvement of Waldenström Macroglobulinemia on 18 F-FDG PET/CT.

Tumor-Associated Macrophage (TAM)-Related Cytokines, sCD163, CCL2, and CCL4, as Novel Biomarkers for Overall Survival and Time to Treatment in Waldenstrom's Macroglobulinemia: Emphasis on Asymptomatic WM.

Cells

Salvage treatment after covalent BTKi failure: An unmet need in clinical practice in Waldenstrom macroglobulinemia.

HemaSphere

Zanubrutinib for the treatment of Bing-Neel syndrome.

International journal of hematology

Zanubrutinib in Japanese treatment-naive and relapsed/refractory patients with Waldenström macroglobulinemia and CLL/SLL.

Experimental and molecular pathology

Diagnostic next-generation sequencing to detect MYD88 L265P in Lymphoplasmacytic lymphoma compared to ddPCR.

A case of renal infiltration by Bence Jones protein kappa-producing lymphoplasmacytic lymphoma.

CEN case reports

Single-cell RNA sequencing defines distinct disease subtypes and reveals hypo-responsiveness to interferon in asymptomatic Waldenstrom's Macroglobulinemia.

Nature communications

Internal medicine (Tokyo, Japan)

Waldenström's Macroglobulinemia/Lymphoplasmacytic Lymphoma Developing Renal AA Amyloidosis: A Case Report and Literature Review.

Two Cases of Prurigo Nodularis in Hematologic Malignancies: Hodgkin Lymphoma and Waldenström Macroglobulinemia.

Hyperviscosity syndrome in Waldenström Macroglobulinemia.

Transfusion

Cancer reports (Hoboken, N.J.)

Chemokine Expression in Well-Differentiated Liposarcoma May Be Involved in the Tumorigenesis of Lymphoplasmacytic Lymphoma: A Case Study.

Journal of cellular and molecular medicine

Covalent Bruton tyrosine kinase inhibitors across generations: A focus on zanubrutinib.

Central nervous system involvement in Waldenström macroglobulinemia: a comparative population-based study of Bing-Neel syndrome and histological transformation.

Annals of hematology

Kidney international reports

Exploratory Immunosequencing of an Intracapillary Monoclonal Deposits Disease in a Patient With Subacute Neuro-Renal Syndrome.

Steroid-resistant nephrotic syndrome as paraneoplastic syndrome of Waldenström macroglobulinemia: a case report.

CEN case reports

Archives of pathology & laboratory medicine

Concomitant Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma and Non-Immunoglobulin M Plasma Cell Neoplasm: A Report of 14 Cases With Laboratory Evidence of Biclonal B-Cell Neoplasms in Individual Patients.

The Journal of dermatology

A case of lymphoplasmacytic lymphoma/Waldenström macroglobulinemia diagnosed with facial lesions.

A Rare Case of Chronic Lymphocytic Leukemia Transforming Into Waldenström Macroglobulinemia During Ibrutinib Therapy.

Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti

Successful treatment of relapsed Waldenström's macroglobulinemia with proteasome inhibitors (bortezomib and subsequently ixazomib) in combination with rituximab and dexamethasone. A case report and review of the of proteasome inhibitors in Waldenström's….

Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti

The treatment combination of obinutuzumab, bendamustine and dexamethasone achieved a deeper response than the previous line of treatment in five patients with Waldenström's macroglobulinemia.

IgM Flare in Anti-MAG Neuropathy Post Rituximab Treatment: A Clinical Case and a Systematic Review of the Literature.

Brain sciences

Therapeutic advances in hematology

Optimal use of BTK inhibitors in Waldenström's macroglobulinemia: combination or single drug approach?

Waldenström Macroglobulinemia-Induced Cardiac Amyloid Light Chain Amyloidosis.

Ochsner journal

Mutational Landscape of Bone Marrow CD19 and CD138 Cells in Waldenström Macroglobulinemia (WM) and IgM Monoclonal Gammopathy of Undetermined Significance (IgM MGUS).

Cancer medicine

Uncovering a lymphoplasmacytic lymphoma/Waldenström macroglobulinemia initially manifesting as dizziness detected through abnormal serum lipemia index: A case report.

Medicine

CD23 expression in lymphoplasmacytic lymphoma: Clinical-pathological and biological correlations.

Histopathology

International journal of hematology-oncology and stem cell research

Sequential Occurrence of Eosinophilic Gastrointestinal Disease in a Case of Waldenström's Macroglobulinemia in Remission: An Unusual Report with Review.

Lymphoplasmacytic lymphoma and Waldenström macroglobulinemia, a decade after the discovery of MYD88L265P.

Human pathology

Expanded tumor-associated polymorphonuclear myeloid-derived suppressor cells in Waldenstrom macroglobulinemia display immune suppressive activity.

Extramedullary disease in Waldenström macroglobulinemia: A population-based observational study.

EJHaem

International journal of molecular sciences

GLI3 Is Required for M2 Macrophage Polarization and M2-Mediated Waldenström Macroglobulinemia Growth and Survival.

Current hematologic malignancy reports

Monoclonal Gammopathy-Associated Neuropathy.

Cancer management and research

Two Cases of Macroglobulinemia with Elevated Serum CA125: Case Reports and Literature Review.

Applied immunohistochemistry & molecular morphology : AIMM

Expression of MYD88 L265P Mutation in Subtypes of Diffuse Large B-Cell Lymphoma in the Pakistani Population.

"Real-Life" Data of Zanubrutinib in Patients with Waldenström Macroglobulinemia: A Multicenter Retrospective Study.

Acta haematologica

Machine learning based on multiplatform tests assists in subtype classification of mature B-cell neoplasms.

Peripheral neuropathy in the phase 3 ASPEN study of Bruton tyrosine kinase inhibitors for Waldenström macroglobulinemia.

A comparative analysis of transformed indolent lymphomas and de novo diffuse large B-cell lymphoma: a population-based cohort study.

Efficacy and safety of bendamustine, rituximab and bortezomib treatment in relapsed/refractory Waldenstrom Macroglobulinaemia: results of phase 2 single-arm FIL-BRB trial.